FAMILY COURT DRUG TESTING Part 2: One Test Doesn’t Tell a Story, But Many Tests Can

How Serial Monitoring Gives Therapeutic Value Conclusions Real Evidentiary Weight

In our previous article, we explored why a single drug test concentration cannot determine dose, frequency, or recency of use — and why pharmacokinetic plausibility (also called therapeutic value), while conceptually appealing, is too unreliable to serve as a forensic tool. This article picks up where that one left off. If a single number can’t answer the questions family court needs answered, what can?

From a Single Test to Serial Data: Why Volume Matters

In our previous article on the Medical Review Officer process, we examined a concept called pharmacokinetic plausibility — also referred to as therapeutic value — the idea that a urine drug concentration can be compared against expected therapeutic ranges to determine whether it is consistent with a prescribed dose. We explained why this concept is scientifically unreliable when applied to a single specimen, but we also noted that the published literature points to a different conclusion when quantitative results are collected over time.

This article picks up where that one left off. The question is no longer whether therapeutic value has a place in family court — it does. The question is how to build the evidentiary foundation that makes therapeutic value conclusions defensible.

Pharmacokinetic plausibility and therapeutic value are not junk science. But their reliability depends entirely on how much data supports them. A single specimen compared to a population average is weak. A donor-specific baseline built from serial monitoring data is strong.

What the Research Says About Serial Quantitative Monitoring

The case for serial monitoring is not theoretical — it is supported by peer-reviewed research across multiple clinical settings.

A peer-reviewed article published in Critical Reviews in Clinical Laboratory Sciences found that while single-specimen quantitative interpretation is complicated by numerous uncontrolled variables, quantitative urinary results can assist in differentiating new drug use from previous use, and that spikes in urinary concentration can assist in identifying patterns of drug use. The same article noted that trending serial data adds interpretive value that no single collection can provide.

A study published in PMC on objective drug testing confirmed that chromatographic methods produce quantitative results that can be used to follow serial samples and determine whether metabolite concentrations are rising or falling — which may suggest ongoing use or abstinence.

A study of 500 chronic pain patients published in Pain Physician found that repeated quantitative urine drug testing improved compliance in nearly 64% of patients who were initially non-compliant. And a separate large-scale retrospective analysis spanning three years of data identified increased opioid adherence in all drugs studied with more frequent testing.

Taken together, this research establishes a clear principle: while a single quantitative urine result cannot reliably support therapeutic value conclusions, serial quantitative data — collected over weeks and months — transforms the analysis from a comparison against population averages into a comparison against the donor’s own established pattern. That is a fundamentally different — and far more defensible — argument.

What Changes When You Have Multiple Results

Serial drug testing — collecting specimens at regular intervals over an extended period — fundamentally changes what the data can tell you. Not because any individual specimen becomes more reliable, but because the collection of results, taken together, reveals something a single test never can: a donor-specific baseline.

Every person metabolizes drugs differently. Every person’s urine pH, hydration habits, and collection timing will vary from day to day. But over the course of twelve, fifteen, or twenty collections, those variables begin to average out. What emerges is a range — a corridor of concentrations that the donor’s results consistently fall within when they are taking a stable dose of a prescribed medication.

This is the critical shift: you are no longer comparing the donor to a population average from a textbook. You are comparing the donor to themselves.

This is what gives therapeutic value conclusions real weight. The fundamental weakness of therapeutic value from a single specimen is that it relies on population-level reference ranges — averages derived from controlled clinical studies that describe what a group of people might produce under controlled conditions. Those ranges do not account for this donor’s metabolism, this donor’s hydration habits, or this donor’s urine pH on the day of collection. A donor-specific baseline built from serial monitoring eliminates that gap entirely. The baseline is the donor’s own data, under their own real-world conditions.

How a Donor-Specific Baseline Works

Imagine a parent who is prescribed 20 mg of Adderall daily as part of a treatment plan that the court is monitoring. Over twelve weekly urine collections, their amphetamine concentrations come back as follows:

Week	ng/mL	Week	ng/mL	Week	ng/mL
1	2,400	5	3,100	9	1,800
2	1,900	6	2,600	10	3,400
3	3,200	7	2,200	11	2,100
4	2,800	8	3,500	12	2,700

These values range from 1,800 to 3,500 ng/mL. There is variability — as expected — but the results cluster within a recognizable corridor. This is what a stable, compliant pattern looks like: noisy but bounded.

Now imagine that week 13 comes back at 14,200 ng/mL.

That result is not just higher than average. It is roughly four times the highest value in the donor’s entire twelve-week history. While any single specimen is still subject to the same uncontrolled variables, a deviation of that magnitude from an established baseline is extremely difficult to attribute to normal day-to-day variability alone. Something changed.

A single result of 14,200 ng/mL, standing alone, is uninterpretable — it could reflect dehydration, acidic urine, or timing. But 14,200 ng/mL following twelve consecutive results between 1,800 and 3,500 is a significant departure from the donor’s own established pattern. That distinction is the entire value of serial monitoring.

How Many Results Do You Need?

There is no published forensic standard that defines the minimum number of specimens required to establish a defensible baseline. However, the logic is straightforward: you need enough data points to capture the normal range of variability in that donor’s results before you can identify a meaningful departure from it.

Fewer than six specimens is generally insufficient. With only a handful of results, you cannot distinguish a genuine pattern from random variation. Three high values and three low values could simply reflect collection timing and hydration differences — not a stable baseline.

Eight to ten specimens begins to provide a usable baseline. At this volume, you start to see a corridor forming. If the donor is stable and compliant, values will cluster within a recognizable range, and an outlier begins to stand out against that backdrop.

Twelve to fifteen specimens is where the argument becomes genuinely strong. Over roughly three months of weekly collections, you have captured the donor across a wide range of normal daily conditions — hydrated days and dehydrated days, morning and afternoon collections, varying urine pH levels. The pattern has had time to establish itself. A significant deviation at specimen thirteen or fourteen is very hard to explain away as routine variability.

Beyond fifteen specimens adds confidence with diminishing returns. If a stable baseline is already established across twelve to fifteen collections, additional specimens confirm the pattern but do not significantly change the strength of the argument.

Collections	Baseline Strength	Recommended Use
Fewer than 6	Insufficient	Not enough data to distinguish pattern from noise
8 – 10	Developing	Corridor begins to form; outliers start to become visible
12 – 15	Strong	Donor-specific baseline established; significant deviations are defensible
15+	Confirmed	Adds confidence with diminishing returns; baseline already reliable

What Serial Monitoring Can and Cannot Prove

Serial monitoring is a significantly more powerful tool than a single test. But it is important to be precise about what it can and cannot do, because overstating the science in court is as dangerous as understating it.

What serial monitoring can do:

It can establish a donor-specific baseline that reflects their individual metabolic profile under real-world conditions. It can identify significant deviations from that baseline that warrant further inquiry. It can demonstrate stability and compliance over time — showing a court that a parent’s results have been consistent with their prescribed medication for weeks or months. And it can shift the burden of explanation: when a result departs dramatically from a well-established pattern, the question becomes what changed — not whether the number is inherently meaningful.

What serial monitoring cannot do:

It cannot prove with certainty why an outlier occurred. A dramatically elevated result could mean the donor took extra medication. It could also mean they were severely dehydrated, had unusually acidic urine that day, or collected very shortly after dosing. The uncontrolled variables that limit single-specimen interpretation do not disappear — they become less dominant over many collections, but they still apply to any individual specimen.

The difference is in how the argument lands. With a single test, an expert saying “this number is too high” can be easily countered by “you can’t know that from one specimen.” With twelve prior results establishing a consistent range, that same expert can say “this result is a significant departure from this donor’s own established pattern” — and the opposing side now has to explain why all the variables happened to align to produce a result four times higher than anything previously seen. That is a much harder argument to make.

Serial monitoring does not eliminate the limitations of urine drug testing. It manages them. By collecting enough data to establish a donor’s own baseline, it transforms a single uninterpretable number into part of a pattern that courts can meaningfully evaluate.

The Strategic Value for Attorneys

For attorneys handling custody or child welfare cases where drug use or medication compliance is at issue, serial monitoring offers something that no single test — and no amount of pharmacokinetic theorizing from a textbook — can provide: evidence grounded in the donor’s own history.

Demonstrating sobriety or compliance: A parent who produces twelve consecutive negative results, or twelve consistent positives for a prescribed medication at stable concentrations, has a documented track record. That is far more persuasive to a judge than a single clean test that could reflect nothing more than fortunate timing.

Identifying potential relapse or misuse: A significant departure from an established baseline raises a legitimate question that the court can evaluate in context. It does not prove misuse on its own, but it provides a factual foundation for further inquiry — additional testing, clinical evaluation, or closer monitoring.

Defending against quantitative misinterpretation: If opposing counsel presents a single elevated result and argues that the concentration proves excessive use, a serial history showing consistent variability within a stable range is the most effective rebuttal available. It demonstrates that the donor’s results have always fluctuated and that one higher value is within the expected noise — not evidence of a change in behavior.

Building a protocol the court can trust: Recommending a serial monitoring schedule — weekly collections over eight to twelve weeks — signals to the court that your approach is systematic, evidence-based, and designed to produce actionable information rather than a single data point that may or may not mean anything.

Practical Recommendations for Family Court Testing

Based on the principles outlined above, the following approach provides the strongest evidentiary foundation for family court cases involving drug testing:

Frequency: Weekly collections are ideal for establishing a baseline within a reasonable timeframe. Biweekly collections can work but require a longer monitoring period to accumulate sufficient data.

Duration: A minimum of eight weeks, with twelve weeks preferred. This produces eight to twelve data points — enough to establish a reliable donor-specific baseline and to identify meaningful deviations.

Consistency: Collections should be observed and follow the same protocols each time. Variations in collection procedure introduce additional variables that complicate interpretation.

Specimen type: Urine is the preferred specimen for serial monitoring because it provides a detection window measured in days and produces quantitative values that can be compared across collections. Hair testing provides a longer lookback but is collected less frequently and is better suited for establishing a broad pattern of use over months rather than week-to-week monitoring.

Expert interpretation: Serial data is most valuable when interpreted by a qualified forensic toxicologist or testing provider who understands the variables that influence urine concentrations. Presenting raw numbers to a court without expert context risks the same misinterpretation that plagues single-specimen results.

References

1. Clarke, W. & Dasgupta, A. (Eds.). “What the lab can and cannot do: clinical interpretation of drug testing results.” Critical Reviews in Clinical Laboratory Sciences, 2020. Taylor & Francis.

2. Levy, S., Siqueira, L.M., et al. “Objective Testing – Urine and Other Drug Tests.” PMC / National Institutes of Health, 2016. (PMC4920965)

3. Knezevic, N.N., Khan, O.M., et al. “Repeated Quantitative Urine Toxicology Analysis May Improve Chronic Pain Patient Compliance with Opioid Therapy.” Pain Physician, 2017; 20: S135–S145.

4. Schreiber, Y.S., Egan, E., et al. “Increased frequency of urine drug testing in chronic opioid therapy: rationale for strategies for enhancing patient adherence and safety.” PMC / National Institutes of Health, 2019. (PMC6661994)

5. Argoff, C.E., Alford, D.P., Fudin, J., et al. “Rational Urine Drug Monitoring in Patients Receiving Opioids for Chronic Pain: Consensus Recommendations.” Pain Medicine, 2018; 19(1): 97–117.

One test is a snapshot. Many tests are a story. In family court, where decisions shape the lives of children and families, the story is what matters. To learn more about serial monitoring protocols and family court drug testing, contact TrueTest Labs.mgammel@truetestlabs.com  |  847.258.3966 TrueTest Labs  |  truetestlabs.com  |  Drug Testing Solutions